Researcher profile · Semantic Scholar

N. Smrekar

h-index: 9
Works: 26
Citations: 265

Most-cited papers

Success and safety of high infliximab trough levels in inflammatory bowel disease
D. Drobne, T. Kurent, Saša Golob, Polona Švegl +17 more
2018Scandinavian Journal of Gastroenterology45 citations
Semantic Scholar
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.
J. Hanžel, J. Zdovc, T. Kurent, N. Sever +11 more
2020Clinical Gastroenterology and Hepatology44 citations Open access
Semantic Scholar
Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease
D. Drobne, T. Kurent, Saša Golob, Polona Švegl +7 more
2019Alimentary Pharmacology and Therapeutics35 citations
Semantic Scholar
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
J. Hanžel, N. Sever, I. Ferkolj, B. S̆tabuc +8 more
2019United European Gastroenterology journal29 citations Open access
Semantic Scholar
Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model
Jurij Aguiar Zdovc, J. Hanžel, T. Kurent, N. Sever +10 more
2021Pharmaceutics23 citations Open access
Semantic Scholar
Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn’s disease
J. Hanžel, M. Koželj, Ana Špes Hlastec, T. Kurent +7 more
2021European Journal of Gastroenterology and Hepathology15 citations
Semantic Scholar
Concentrations of 222Rn and 220Rn in Indoor Air
J. Vaupotič, I. Čeliković, N. Smrekar, Z. Žunić +1 more
200815 citations
Semantic Scholar
IgA Nephropathy in a Patient Treated with Adalimumab
Tonja Mertelj, N. Smrekar, N. Kojc, J. Lindič +1 more
2021Case Reports in Nephrology and Dialysis14 citations Open access
Semantic Scholar
Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label
S. Stefanovic, I. Detrez, G. Compernolle, E. Brouwers +9 more
2020European Journal of Gastroenterology and Hepathology9 citations
Semantic Scholar
Comparison of radon doses based on different radon monitoring approaches.
J. Vaupotič, N. Smrekar, Z. Žunić
2017Journal of Environmental Radioactivity9 citations
Semantic Scholar
Dendritic Cell Profiles in the Inflamed Colonic Mucosa Predict the Responses to Tumor Necrosis Factor Alpha Inhibitors in Inflammatory Bowel Disease
N. Smrekar, D. Drobne, Lojze M. Šmid, I. Ferkolj +3 more
2018Radiology and Oncology7 citations Open access
Semantic Scholar
Insights into treatment of complex Crohn's perianal fistulas
G. Norčič, N. Smrekar, Srđan Marković, Goran Barišić +8 more
2024BMC Proceedings6 citations Open access
Semantic Scholar
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease
Š. Pintar, J. Hanžel, D. Drobne, M. Koželj +3 more
2024Medicina6 citations Open access
Semantic Scholar
P632 Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitis
S. Stefanovic, I. Detrez, G. Compernolle, E. Brouwers +9 more
20182 citations Open access
Semantic Scholar
Sa1980 High Infliximab Trough Levels Are Associated With Better Control of Inflammation in IBD
D. Drobne, T. Kurent, Polona Rajar, M. Slak +8 more
20162 citations
Semantic Scholar
Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis
G. Novak, N. Sever, J. Hanžel, M. Koželj +4 more
2023European Journal of Gastroenterology and Hepathology1 citations
Semantic Scholar
P702 Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel Disease
Š. Pintar, J. Hanžel, N. Smrekar, M. Koželj +4 more
2023Journal of Crohn's & Colitis1 citations Open access
Semantic Scholar
P720 Drug survival of first-line biologics in inflammatory bowel disease: large single-centre experience from UR-CARE
J. Hanžel, E. Supovec, N. Smrekar, M. Koželj +4 more
2023Journal of Crohn's & Colitis1 citations Open access
Semantic Scholar
P603 Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease
J. Hanžel, N. Sever, I. Ferkolj, B. S̆tabuc +5 more
20181 citations Open access
Semantic Scholar
Mo1836 - Vedolizumab Trough Levels at Week 6 Predict Endoscopic and Clinical Remission in Inflammatory Bowel Disease
J. Hanžel, N. Sever, I. Ferkolj, B. S̆tabuc +5 more
20181 citations
Semantic Scholar
P0772 Efficacy and consumption of golimumab is similar with European and American dosing regimens in Ulcerative Colitis: Results of a prospective study
I. Milanez, S. Finderle, J. Hanžel, G. Novak +9 more
2025Journal of Crohn's & Colitis0 citations
Semantic Scholar
Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres – prime time for decentralisation of inflammatory bowel disease care?
Katja Tepes, J. Hanžel, D. Štubljar, Karin Strmšek +30 more
2024European Journal of Gastroenterology and Hepathology0 citations Open access
Semantic Scholar
N17 Frequency of infliximab-induced skin lesions and their impact on quality of life in inflammatory bowel disease patients treated with infliximab
C. Bobnar Sekulic, T. Polanc, U. Koren, T. Kurent +4 more
2019Journal of Crohn's & Colitis0 citations
Semantic Scholar
P686 Neither high infliximab maintenance doses nor high trough levels trigger skin side effects of the drug: a prospective cross-sectional study
T. Kurent, U. Koren, J. Hanžel, M. Koželj +5 more
2019Journal of Crohn's & Colitis0 citations
Semantic Scholar
Golimumab Trough Levels Predict Mucosal Healing and Success of Dose Optimization: A Prospective Observational Study
S. Stefanovic, I. Detrez, G. Compernolle, E. Brouwers +10 more
2018American Journal of Gastroenterology0 citations
Semantic Scholar
ASSESSMENT OF EFFECTIVE DOSES BASED ON VARIOUS RADON MEASURING TECHNIQUES
N. Smrekar
20160 citations
Semantic Scholar

T. Kurent

×16

J. Hanžel×13

N. Sever×11

I. Ferkolj×8

A. Gils×6

G. Compernolle×4

Polona Rajar×3

I. Grabnar×3